About Us

About Us

Newormics is a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models as well as in vitro 3D tissue organoids. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.

At Newormics we are committed to empowering every scientist, research lab and drug discovery industry, to make discoveries faster with our modern and simple technology.

Newormics was co-founded in 2016 by Prof. Adela Ben-Yakar and Evan Hegarty and is a spinoff from the Ben-Yakar Lab in the Mechanical Engineering Department at the University of Texas at Austin.

Our Team